Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker

LRRK2 dephosphorylation increases its ubiquitination

(2015) Jing Zhao et al.   BIOCHEMICAL JOURNAL

Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease

(2015) Paul Gilligan   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration

(2015) João P. L. Daher et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)

(2014) Raghava R Kethiri et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor

(2014) Jaclyn L. Henderson et al.   JOURNAL OF MEDICINAL CHEMISTRY

LRRK2 pathobiology in Parkinson's disease

(2014) Ian Martin et al.   JOURNAL OF NEUROCHEMISTRY

Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic

(2014) Andrew B. West   MOVEMENT DISORDERS

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

(2014) Mike A Nalls et al.   NATURE GENETICS

Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7

(2014) Ruth Chia et al.   Nature Communications

Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle

(2013) Evy Lobbestael et al.   BIOCHEMICAL JOURNAL

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies

(2013) Paul Davies et al.   BIOCHEMICAL JOURNAL

GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor

(2012) Alastair D. Reith et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)

(2012) Xianming Deng et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity

(2012) C. Yao et al.   HUMAN MOLECULAR GENETICS

Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation

(2012) Lore Delbroek et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling

(2012) Nicolas Dzamko et al.   PLoS One

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models

(2011) Zhaohui Liu et al.   HUMAN MOLECULAR GENETICS

Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures

(2011) Mansoureh Hakimi et al.   JOURNAL OF NEURAL TRANSMISSION

Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson’s disease mutations and LRRK2 pharmacological inhibition

(2011) Elizabeth A. Doggett et al.   JOURNAL OF NEUROCHEMISTRY

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2

(2011) Xianming Deng et al.   Nature Chemical Biology

Phosphorylation-Dependent 14-3-3 Binding to LRRK2 Is Impaired by Common Mutations of Familial Parkinson's Disease

(2011) Xianting Li et al.   PLoS One

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization

(2010) Nicolas Dzamko et al.   BIOCHEMICAL JOURNAL

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

(2010) R. Jeremy Nichols et al.   BIOCHEMICAL JOURNAL

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

(2010) Byoung Dae Lee et al.   NATURE MEDICINE

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

(2009) Wataru Satake et al.   NATURE GENETICS

Genome-wide association study reveals genetic risk underlying Parkinson's disease

(2009) Javier Simón-Sánchez et al.   NATURE GENETICS

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

(2008) Daniel G Healy et al.   LANCET NEUROLOGY

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS